US FDA approves Watson's Gelnique for overactive bladder
This article was originally published in Scrip
The US FDAhas approved Watson Pharmaceuticals' muscarinic antagonist Gelnique (oxybutynin chloride) gel 10% – a topical treatment for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.